Matwin
MATWIN is a French open-innovation acceleration platform dedicated exclusively to oncology, operating as a subsidiary of Unicancer (the 18 French Cancer Centers). It runs a structured acceleration programme, the annual MEET2WIN partnering convention, and an International Board of 13+ pharmaceutical companies that evaluates and labels early-stage academic and startup oncology projects.
- Company typePrivate
- Founded2009
- HeadquartersBordeaux, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Matwin does
MATWIN (Maturation & Accelerating Translation With Industry) is the only French open-innovation platform specifically dedicated to oncology. Founded in 2009 as a wholly-owned subsidiary of Unicancer (the hospital group uniting all 18 French Cancer Centers), MATWIN is headquartered in Bordeaux, France, and operates with a small core team (1-10 employees) under CEO Luc Delporte and President Pr. Norbert Vey. The platform accompanies oncology innovation projects from academia and early-stage startups through a structured three-stage process: a preselection pitch before a multidisciplinary jury, two coaching sessions and one mentoring session, and a final audition before the International Board, which labels projects with the strongest industrial development potential. Since 2009, MATWIN has accompanied over 300 projects and contributed to the creation of more than 50 startups.
The platform's product portfolio comprises the core Acceleration Programme (Programme accélérateur), the annual European MEET2WIN partnering convention (11th edition planned for 2026), the OUI Investment funding-support program, the OncoSTART entrepreneurship consortium, tailor-made support services (Accompagnement à façon), and the International Board labelling process. Underpinning the offering is an International Board staffed by R&D decision-makers from 13 international pharmaceutical and biotech groups (Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, Insitro, MSD, Pfizer, Pierre Fabre, Roche, Sanofi, Takeda, plus Daiichi-Sankyo and Servier) and academic key opinion leaders from major European cancer institutes.
The business model operates as professional services funded by industrial partner contributions and institutional backing from the Unicancer group; pricing is not publicly disclosed and contracts are structured on a multi-year basis. Demand is generated through year-round calls for applications, academic-ecosystem referrals (Canceropoles, SIRIC, SATTs, incubators, clusters), and the annual MEET2WIN convention. Customer segments are threefold and defined as persons/business units: academic oncology research teams across Europe, early-stage oncology biotech and medtech startups, and international pharmaceutical companies. Distribution relies on direct application processing, the academic partner referral network, and the MEET2WIN event as a flagship sourcing and visibility touchpoint.
Matwin firmographics
Firmographics- Name
- Matwin
- Legal name
- MATWIN SAS
- Website
- https://matwin.fr
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MATWIN is a French open-innovation acceleration platform dedicated exclusively to oncology, operating as a subsidiary of Unicancer (the 18 French Cancer Centers). It runs a structured acceleration programme, the annual MEET2WIN partnering convention, and an International Board of 13+ pharmaceutical companies that evaluates and labels early-stage academic and startup oncology projects.
- Ownership category
- akta.pro rank
Matwin industry classification
Industry- Product category
- Oncology Innovation Acceleration Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Management Consulting Services (8742)
- akta.pro primary industry
- Accelerators & Incubators (Investor-Operated) (FSANAAAM)
- akta.pro secondary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where Matwin is headquartered
LocationHeadquarters
- HQ city
- Bordeaux
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Matwin business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Accelerator Program Fees: MATWIN operates as a subsidiary of the Unicancer group and generates revenue through its acceleration program services and expertise offerings. The platform is funded by industrial partners and public/academic collaborators who pay to access pre-filtered innovation projects.
- Annual Partnering Event (MEET2WIN): MEET2WIN is an annual European oncology partnering convention that facilitates connections between academic innovators and industrial partners. The event serves as a revenue-generating activity while also functioning as a project sourcing mechanism.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Tailored expertise and coaching services are offered to academic teams and startups throughout the year on a bespoke basis. |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Matwin product offering
Product offeringCore offering
MATWIN operates an open-innovation acceleration platform exclusively dedicated to oncology. It provides a structured acceleration program (preselection pitch, coaching, mentoring, and Board audition) for academic teams and early-stage startups, accompanied by an annual MEET2WIN partnering convention, the OUI Investment support program, the OncoSTART entrepreneurship consortium, and tailor-made expertise services for oncology innovation projects.
Product overview
MATWIN operates as an open-innovation acceleration platform for oncology, offering a multi-component service portfolio centered around its core acceleration programme. The platform provides structured accompaniment through coaching, mentoring, and international board evaluation; annual MEET2WIN partnering conventions for networking; OUI Investment for funding support; and OncoSTART for entrepreneurship development. Projects progress through a three-stage process: pre-selection pitch, coaching and mentoring sessions, and MATWIN Board audition. The platform also offers tailor-made expertise services and operates a call for projects open to European academic teams and startups.
Differentiator
Problem solved
Functional benefit
Brands
- MEET2WIN: Annual European partnering convention dedicated to open innovation in oncology
- OUI Investment
- OncoSTART
- Accelerator Programme
Products and services
- Programme accélérateur (Acceleration Programme) Structured acceleration program that guides academic teams and startups through coaching sessions, mentoring, and board presentations to optimize the industrial development of oncology projects.
- MEET2WIN Annual European partnering convention dedicated to open innovation in oncology, connecting academic researchers, biotech companies, and pharmaceutical industry partners for networking and business development.
- OUI Investment Investment support program designed to help innovative oncology projects secure funding from investors and financial partners.
- OncoSTART Consortium supporting entrepreneurship in oncology, helping entrepreneurs develop and launch their ventures in the cancer research field.
- Accompagnement à façon (Tailor-made support) Customized expertise and support services offered to projects throughout the year, providing tailored assistance beyond the standard acceleration program.
- International Board Labellisation Project evaluation and labelling service where international academic and industrial experts review and endorse projects with the strongest industrial development potential.
- Appel à projets MATWIN (MATWIN Call for Projects) Open call for oncology innovation projects, accepting applications year-round from European academic teams and startups.
Quantifiable outcome
- Over 300 projects accompanied since 2009
- +2 more outcomes
Companies that use Matwin
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Matwin technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Matwin partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered core and supporting.
- AmgencoreAmgen is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, providing access to its global oncology R&D pipeline and participating in the International Board evaluation process.
- AstraZenecacoreAstraZeneca is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, contributing to the sourcing and evaluation of early-stage oncology innovations in France.
- Boehringer-IngelheimcoreBoehringer-Ingelheim is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, participating in Board evaluations and providing industry perspective on project potential.
- Bristol-Myers SquibbcoreBristol-Myers Squibb is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, contributing to the evaluation of oncology innovation projects through its participation in the International Board.
- Exact SciencescoreExact Sciences is one of the 13 international pharmaceutical/diagnostic groups actively engaged as an industrial partner in the MATWIN program, focusing on oncology precision diagnostics.
- GlaxoSmithKlinecoreGlaxoSmithKline is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program.
- InsitrocoreInsitro is one of the 13 international pharmaceutical/biotech groups actively engaged as an industrial partner in the MATWIN program, bringing machine learning and data-driven drug discovery perspectives to the Board.
- MSDcoreMSD (Merck Sharp & Dohme) is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, participating in the International Board evaluation of oncology projects.
- PfizercorePfizer is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, contributing to the evaluation and potential industrialization of oncology innovation projects.
- Pierre FabrecorePierre Fabre is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, with Anna Kruczynski serving as the Board member representing Pierre Fabre on the International Board.
- RochecoreRoche is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, participating in Board evaluations of oncology innovation projects.
- SanoficoreSanofi is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, with Valeria Fantin serving as the Board member representing Sanofi as Worldwide Head of Oncology Research.
- TakedacoreTakeda is one of the 13 international pharmaceutical groups actively engaged as an industrial partner in the MATWIN program, participating in the sourcing and evaluation of oncology innovations.
- Paris Saclay Cancer Cluster (PSCC)coreMATWIN and the Paris Saclay Cancer Cluster announced a partnership in May 2023 to accelerate efforts in the fight against cancer. PSCC is a cancer-focused cluster that works with MATWIN to identify and support high-potential oncology projects with transfer capability.
- MabDesignsupportingMabDesign is part of the associated partner network of MATWIN, providing biotech sector expertise and network connections.
- Voisin ConsultingsupportingVoisin Consulting is part of the associated partner network of MATWIN, providing regulatory and drug development consulting expertise to accompanied projects.
- ServiercoreServier is listed as an active partner of MATWIN with Alix Scholer-Dahirel serving as Director of Global Business Development at Servier and a member of the MATWIN International Board.
- Daiichi-SankyocoreDaiichi-Sankyo is listed as an active partner of MATWIN with Mark Paris serving as Executive Director and Global Head of Oncology Research and Evaluation at Daiichi-Sankyo and a member of the MATWIN International Board.
- UnicancercoreMATWIN is a wholly-owned subsidiary of Unicancer, the hospital group exclusively dedicated to cancer care that brings together the 18 French Cancer Centers. Unicancer provides institutional backing, access to the national cancer center network, and strategic direction to MATWIN.
- NanostringsupportingMATWIN and Nanostring formed a strategic alliance on translational innovation in oncology. Nanostring provides spatial genomics and gene expression analysis capabilities that complement MATWIN's supported projects.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Matwin competitors and assessment
Company assessmentBroad incumbents
- JLABS (Johnson & Johnson Innovation): Global pharma-anchored biotech incubator network operated by Johnson & Johnson Innovation with structured coaching, mentoring, and pharma-partner engagement for early-stage life sciences startups including oncology. Mirrors MATWIN's pharma-backed accelerator model at a globally larger scale with broader therapeutic scope.
- AstraZeneca BioVentureHub: Sweden-based pharma-anchored life sciences innovation hub where startups and academic teams co-locate with AstraZeneca R&D, mirroring MATWIN's pharma-co-location and open-innovation approach. Functions as both a partner and a potential competitor to MATWIN for European oncology talent.
- Bayer Leaps / CoLaborator: Pharma-backed life science accelerator from Bayer providing infrastructure and expertise to early-stage biotech companies in life sciences including cell and gene therapy and oncology. Comparable to MATWIN's pharma-anchored open-innovation model, though operated within a single pharma partner rather than a multi-pharma consortium.
Direct peers
- LabCentral: Leading US-based biotech incubator in Cambridge, MA providing shared infrastructure, structured acceleration, and connections to pharma partners for early-stage life sciences startups. Directly comparable to MATWIN's accelerator/incubation model and methodology for biotech projects, though MATWIN is oncology-focused while LabCentral serves broader life sciences.
- IndieBio: Biotech-focused accelerator operating programs in NYC and SF providing mentorship, seed funding, and lab access to life sciences startups. Comparable to MATWIN's structured acceleration methodology for biotech projects, with similar focus on early-stage company formation.
- Institut Curie: French oncology research and treatment center running technology transfer, spinoff creation, and industrial partnership programs. Operates in the same French oncology innovation ecosystem as MATWIN with overlap in academic-to-industry translation and a similar mission to accelerate oncology research toward clinical application.
- Cancer Research UK Commercial Partnerships: UK-based commercialization arm of Cancer Research UK that runs partnership programs connecting academic oncology researchers to industry partners. Mirrors MATWIN's open-innovation approach in oncology R&D translation and operates as a competing/parallel national champion in a different European country.
- BioGenerator: US-based biotech accelerator/generator creating and funding life sciences startups in St. Louis. Provides similar acceleration, infrastructure, and industry connection services to biotech startups as MATWIN does for oncology projects in France, with comparable mission to commercialize academic life sciences research.
Others
- EIT Health: European partnership of health innovation accelerators and ecosystem programs. Provides comparable acceleration services across Europe for health and life sciences (including oncology), competing for projects and partnerships within the European health innovation ecosystem and serving as a potential collaborator.
Regional players
- MaRS Discovery District: Canadian health and cleantech innovation hub in Toronto running structured acceleration programs for life sciences startups. Comparable in mission to MATWIN as an open-innovation ecosystem for life sciences including oncology, but operating primarily in North America rather than Europe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Matwin social profiles
Digital presenceMatwin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Matwin leadership team
Management profileNumber of profiles
Profiles7 records
Matwin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Matwin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Matwin
What does Matwin do?
MATWIN operates an open-innovation acceleration platform exclusively dedicated to oncology. It provides a structured acceleration program (preselection pitch, coaching, mentoring, and Board audition) for academic teams and early-stage startups, accompanied by an annual MEET2WIN partnering convention, the OUI Investment support program, the OncoSTART entrepreneurship consortium, and tailor-made expertise services for oncology innovation projects.
Is Matwin a public or private company?
Matwin is a private company. It is classified as corporate owned and is currently operating.
When was Matwin founded?
Matwin was founded in 2009. It employs 1 to 10 people.
Where is Matwin based?
Matwin is headquartered in Bordeaux, France, in the Europe region.
How does Matwin make money?
Two revenue lines are on record. Accelerator Program Fees are the primary driver. The others are annual Partnering Event (MEET2WIN).
Who are Matwin's main competitors?
Broad incumbents on record are JLABS (Johnson & Johnson Innovation), AstraZeneca BioVentureHub and Bayer Leaps / CoLaborator. Direct peers are LabCentral, IndieBio, Institut Curie, Cancer Research UK Commercial Partnerships and BioGenerator. EIT Health is listed as an others. MaRS Discovery District is listed as a regional player.
Does Matwin have an API?
No public API is recorded for Matwin.
What industry is Matwin in?
Matwin's product category is Oncology Innovation Acceleration Services. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 54169 and its SIC code is 8742.